Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Golden_Cross, lakingsphan0427 , $Pistol Pete$
Search This Board: 
Last Post: 3/20/2019 1:20:58 PM - Followers: 412 - Board type: Free - Posts Today: 4


     WEEKLY NUMBERS     http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116919069
Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at: http://www.mannkindcorp.com/about-us-overview.htm#sthash.6MYBImtD.dpuf


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge


http://www.mnkd.proboards.com/  A good forum for discussion on Mankind


MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.





Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Amended Statement of Changes in Beneficial Ownership (4/a) 03/13/2019 12:22:32 PM
MNKD News: Amended Statement of Changes in Beneficial Ownership (4/a) 03/13/2019 12:21:55 PM
MNKD News: Amended Statement of Changes in Beneficial Ownership (4/a) 03/13/2019 12:21:02 PM
MNKD News: Amended Statement of Changes in Beneficial Ownership (4/a) 03/13/2019 12:20:19 PM
MNKD News: Annual Report (10-k) 02/26/2019 08:16:35 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#30134  Sticky Note $MNKD Early Insulin Therapy for Type 2 testing $Pistol Pete$ 09/03/18 12:26:56 PM
#27521  Sticky Note From the MNKD proboards -->> TTIME 02/14/18 02:49:38 PM
#31482   Yeah shorts aren't going to go away that Hypi 03/20/19 01:20:58 PM
#31481   Big blocks of buys coming in. martind18 03/20/19 09:51:25 AM
#31480   Yes, Looking real strong here. Just a matter Golden_Cross 03/20/19 01:22:40 AM
#31479   UTHR CEO today at Oppenheimer's conference talking about Hypi 03/20/19 12:07:11 AM
#31478   I hope soon. Like really soon lol BluSkies 03/19/19 04:08:11 PM
#31477   Great points! BluSkies 03/19/19 04:07:42 PM
#31476   Will be seeing 3's soon. Imho Go4itbigtime 03/19/19 01:19:21 PM
#31475   Going to be a nice ride from here Hypi 03/19/19 12:47:37 PM
#31474   50MA on a head on collision with the BluSkies 03/19/19 11:21:46 AM
#31473   Interesting....https://www.biospace.com/article/-am6a-mannkind-and-united-therap BluSkies 03/18/19 09:04:13 PM
#31472   Drs probably don’t think it’s as effective as BluSkies 03/18/19 11:29:06 AM
#31471   Money Flow Very Strong into $MNKD Golden_Cross 03/18/19 11:03:29 AM
#31470   Major paradigm move with Afrezza. Diabetics and Dr's Hypi 03/18/19 10:50:50 AM
#31469   Looking good early. Golden_Cross 03/18/19 10:06:57 AM
#31468   Soon BluSkies! Golden_Cross 03/18/19 10:04:52 AM
#31467   Golden Cross soon BluSkies 03/18/19 09:46:00 AM
#31466   actually, the odds are in favor of NO SidVicious 03/18/19 07:20:59 AM
#31465   Going to be a fun ride and a Hypi 03/17/19 10:31:12 PM
#31464   Chart looking very Bullish. 50/200dma getting closer to Golden_Cross 03/16/19 08:21:06 PM
#31463   Monthly OPEX caused some wild moves today and Hypi 03/16/19 12:49:58 AM
#31462   * * $MNKD Video Chart 03-15-2019 * * ClayTrader 03/15/19 04:06:07 PM
#31461   Wow. Big buys today. Just noticing. wedman 03/15/19 04:05:38 PM
#31460   Bring it on! lakingsphan0427 03/14/19 11:21:33 PM
#31459   Wow https://seekingalpha.com/article/4247023-arena-mannkind-associated-somethin BluSkies 03/14/19 09:55:28 PM
#31458   * * $MNKD Video Chart 03-14-2019 * * ClayTrader 03/14/19 05:05:56 PM
#31457   $10 already! BluSkies 03/14/19 04:45:39 PM
#31456   When the squeeze starts it will not be Profit 03/14/19 04:15:49 PM
#31455   Are we officially on a short squeeze guys lakingsphan0427 03/14/19 11:55:34 AM
#31454   Beast mode BluSkies 03/14/19 11:51:42 AM
#31453   WHOA! look at that up another 6% I lakingsphan0427 03/14/19 11:43:28 AM
#31452   sponsoring Conor Daly, Indy car driver, is some purdue pete 03/14/19 11:41:48 AM
#31451   And the uptrend continues boys and girls.. GO MNKD! lakingsphan0427 03/14/19 09:58:22 AM
#31450   Interest picking up here. Mnkd should be over harry crumb 03/14/19 09:09:06 AM
#31449   Hopefully soon! So with yesterday’s insider purchases I BluSkies 03/14/19 08:04:01 AM
#31448   Someone is going to soon step up and STOCKSEEK 03/14/19 07:51:12 AM
#31447   Good stuff Hypi.. If they actually announced this lakingsphan0427 03/14/19 01:44:50 AM
#31446   Adcirca by UTHR with MNKD will be announced Hypi 03/14/19 12:20:32 AM
#31445   * * $MNKD Video Chart 03-13-2019 * * ClayTrader 03/13/19 04:59:36 PM
#31444   When do script numbers come out? BluSkies 03/13/19 04:23:04 PM
#31443   Form 4 filed.. Its great to see insider lakingsphan0427 03/13/19 03:53:21 PM
#31442   2.20 was warning, 2.40 is next 3antar 03/13/19 03:34:47 PM
#31441   Looking at lot better at 2.20+ oh well BluSkies 03/13/19 03:24:34 PM
#31440   Yes he will ! Ugh right! wedman 03/13/19 10:32:08 AM
#31439   They are dotting all the "i's and crossing Go4itbigtime 03/13/19 10:20:15 AM
#31438   $MNKD $3 next resistance :) TradeNaked 03/13/19 10:19:12 AM
#31437   Whoa! BluSkies 03/13/19 10:13:24 AM
#31436   MNKD is on fire! F yeah.. GO MNKD lakingsphan0427 03/13/19 09:41:03 AM
#31435   Like I said "don't worry about the scrips Hypi 03/13/19 01:20:19 AM
#31434   Great day today volume building looking strong. Profit 03/12/19 08:26:46 PM
#31433   Good close today keep 'er going.. GO MNKD! lakingsphan0427 03/12/19 07:46:02 PM